Cargando…
The Genomic Landscape of Radioactive Iodine Refractory and Avid Papillary Thyroid Carcinomas
Background: Although, standard treatment of Papillary Thyroid Carcinoma (PTC), involving surgery followed by radioactive iodine (RAI) therapy, is curative for most patients, 5-20% of patients develop RAI refractory disease. The repertoire of genomic events enabling RAI refractory disease in PTC need...
Autores principales: | Al-Kuraya, Khawla Sami, Siraj, Sarah, Masoodi, Tariq, Siraj, Abdul Khalid, Azam, Saud, Qadri, Zeeshan, Al-Dayel, Fouad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090190/ http://dx.doi.org/10.1210/jendso/bvab048.1779 |
Ejemplares similares
-
Whole-Exome Sequencing of Matched Primary and Metastatic Papillary Thyroid Cancer
por: Masoodi, Tariq, et al.
Publicado: (2020) -
APOBEC SBS13 Mutational Signature—A Novel Predictor of Radioactive Iodine Refractory Papillary Thyroid Carcinoma
por: Siraj, Sarah, et al.
Publicado: (2022) -
Whole Exome-Wide Association Identifies Rare Variants in GALNT9 Associated with Middle Eastern Papillary Thyroid Carcinoma Risk
por: Bu, Rong, et al.
Publicado: (2023) -
Annual Hazard Rate of Recurrence in Middle Eastern Papillary Thyroid Cancer over a Long-Term Follow-Up
por: Siraj, Abdul K., et al.
Publicado: (2020) -
Exome sequencing revealed comparable frequencies of RNF43 and BRAF mutations in Middle Eastern colorectal cancer
por: Siraj, Abdul Khalid, et al.
Publicado: (2022)